-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 This Phase III clinical trial is a randomized, double-blind, ...
Between balancing schoolwork and dealing with hormonal changes, the teenage experience can be challenging. Perhaps the most common and frustrating of them all are frequent breakouts. Acne affects an ...
HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback